$WVE| AASLD 2026 — WVE-006 Late-Breaking Presentation
What’s new? Today’s AASLD presentation formally highlights RestorAATion-2’s human RNA-editing results, reinforcing the potential for a single therapy addressing BOTH lung and liver disease in AATD. Importantly, the efficacy figures largely confirm May’s disclosures rather than represent a new data breakthrough.
Positives:
• Functional M-AAT reached 64% of total AAT, approaching the protective MZ-like phenotype.
• Mutant Z-AAT reduced up to 71%.
• Endogenous AAT increased during inflammatory responses.
• Editing durability of at least three months after dosing.
• Favorable safety, no serious AEs.
• FDA alignment on a potential accelerated approval pathway.
Negatives/Risks:
• Limited incremental efficacy data today.
• Absolute functional M-AAT trough levels and clinical lung protection remain unproven.
• No direct evidence of reduced hepatic fibrosis.
• Small cohorts; 600 mg monthly multidose data pending.
Bottom line: Compelling proof of mechanism with potentially best-in-class differentiation, but clinical benefit remains to be demonstrated. The upcoming 600 mg data could be the real valuation inflection point.
Still bullish and holding.
$WVE #RNAEditing #AASLD2026